Sponsors

Company Profile

Endocyte

Cancer
Autoimmune
Inflammation

3000 Kent Avenue
Suite A1-100
West Lafayette, IN 47906
USA
www.endocyte.com 		Incorporated in 1996
45 Employees 		Privately Held

This Year's Highlights

  • Technology platform has produced three product candidates currently in clinical development and two promising product candidates in pre-clinical development. EC145 (Targeted Chemotherapeutic) commenced Phase 1 Clinical Trials.
  • Raised $62 million in capital.
  • License agreement with Bristol-Myers Squibb (January 2006). Agreement gives BMS access to Endocyte's vitamin-targeting technology to target proprietary epothilone cancer chemotherapeutic agents.

Anticipated Highlights

  • In 2007: Three product candidates in phase 2 trials (EC17, EC145, and EC20) Two additional oncology drugs will advance to clinical trials (EC0225 and BMS753493)
  • Close Mezzanine financing round in 1Q07

Corporate Mission

Endocyte is developing novel therapeutics for the treatment of cancer and autoimmune diseases using proprietary receptor-targeting technology.